AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway. This evidence concerns the gene SMAD3 and intrahepatic cholangiocarcinoma.